Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 24657506)

1.

Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.

Rickert V, Haefeli WE, Weiss J.

Pulm Pharmacol Ther. 2014 Aug;28(2):130-7. doi: 10.1016/j.pupt.2014.02.004. Epub 2014 Mar 21.

PMID:
24657506
2.

Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.

Weiss J, Haefeli WE.

Int J Antimicrob Agents. 2013 May;41(5):484-7. doi: 10.1016/j.ijantimicag.2013.01.004. Epub 2013 Feb 18.

PMID:
23428312
3.

Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.

Weiss J, Becker JP, Haefeli WE.

Int J Antimicrob Agents. 2014 Feb;43(2):184-8. doi: 10.1016/j.ijantimicag.2013.10.003. Epub 2013 Nov 5.

PMID:
24332840
4.

Desmethyl bosentan displays a similar in vitro interaction profile as bosentan.

Weiss J, Baumann S, Theile D, Haefeli WE.

Pulm Pharmacol Ther. 2015 Feb;30:80-6. doi: 10.1016/j.pupt.2014.12.001. Epub 2014 Dec 19.

PMID:
25535031
5.

Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.

Weiss J, Haefeli WE.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1093-8. doi: 10.1007/s00280-011-1715-8. Epub 2011 Jul 31.

PMID:
21805352
6.

Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro.

Weiss J, Theile D, Dvorak Z, Haefeli WE.

Pharmaceutics. 2014 Dec 16;6(4):632-50. doi: 10.3390/pharmaceutics6040632.

7.

Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.

Weiss J, Theile D, Rüppell MA, Speck T, Spalwisz A, Haefeli WE.

Eur J Pharmacol. 2013 Feb 15;701(1-3):168-75. doi: 10.1016/j.ejphar.2013.01.010. Epub 2013 Jan 23.

PMID:
23353592
8.

In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.

Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, Green MD, Kuo Y, Liang Y, Maciolek CM, Palamanda J, Evers R, Prueksaritanont T.

Drug Metab Dispos. 2013 Mar;41(3):668-81. doi: 10.1124/dmd.112.049668. Epub 2013 Jan 4.

9.

In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.

Reyner EL, Sevidal S, West MA, Clouser-Roche A, Freiwald S, Fenner K, Ullah M, Lee CA, Smith BJ.

Drug Metab Dispos. 2013 Aug;41(8):1575-83. doi: 10.1124/dmd.113.051193. Epub 2013 May 31.

10.

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW.

Drug Metab Dispos. 2013 Feb;41(2):353-61. doi: 10.1124/dmd.112.048918. Epub 2012 Nov 6.

11.

Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.

Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L.

Psychopharmacol Bull. 2009;42(2):47-63.

PMID:
19629022
12.

The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP.

Sun S, Chen Z, Li L, Sun D, Tian Y, Pan H, Bi H, Huang M, Zeng S, Jiang H.

Xenobiotica. 2012 Dec;42(12):1197-205. doi: 10.3109/00498254.2012.702247. Epub 2012 Aug 19.

PMID:
22900779
13.

Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.

Theile D, Haefeli WE, Weiss J.

Endocrine. 2014 Dec 27. [Epub ahead of print]

PMID:
25542188
14.

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.

Lang M, Kojonazarov B, Tian X, Kalymbetov A, Weissmann N, Grimminger F, Kretschmer A, Stasch JP, Seeger W, Ghofrani HA, Schermuly RT.

PLoS One. 2012;7(8):e43433. doi: 10.1371/journal.pone.0043433. Epub 2012 Aug 17.

15.

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.

Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bölkow D, Weissmann N, Mück W, Unger S, Wensing G, Schermuly RT, Ghofrani HA.

Eur Respir J. 2009 Apr;33(4):785-92. doi: 10.1183/09031936.00039808. Epub 2009 Jan 7.

16.

Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.

Belik J.

Curr Opin Investig Drugs. 2009 Sep;10(9):971-9. Review.

PMID:
19705340
17.

Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.

Jeong HU, Kwon M, Lee Y, Yoo JS, Shin DH, Song IS, Lee HS.

Drug Des Devel Ther. 2015 Jan 22;9:643-53. doi: 10.2147/DDDT.S75400. eCollection 2015.

18.

Soluble guanylate cyclase stimulators in pulmonary hypertension.

Stasch JP, Evgenov OV.

Handb Exp Pharmacol. 2013;218:279-313. doi: 10.1007/978-3-642-38664-0_12. Review.

PMID:
24092345
19.

Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.

Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J, Ewert R, Weimann G, Grimminger F.

Eur Respir J. 2010 Oct;36(4):792-9. doi: 10.1183/09031936.00182909. Epub 2010 Jun 7.

20.

The potential of Sutherlandia frutescens for herb-drug interaction.

Fasinu PS, Gutmann H, Schiller H, James AD, Bouic PJ, Rosenkranz B.

Drug Metab Dispos. 2013 Feb;41(2):488-97. doi: 10.1124/dmd.112.049593. Epub 2012 Dec 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk